Lexiscan
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $38,897 | 159 | 141 |
| 2022 | $106,673 | 1,240 | 925 |
| 2021 | $17.52 | 1 | 1 |
| 2017 | $531,672 | 8,580 | 4,342 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $286,560 | 97 | 42.3% |
| Food and Beverage | $187,145 | 9,691 | 27.6% |
| Space rental or facility fees (teaching hospital only) | $74,045 | 50 | 10.9% |
| Consulting Fee | $66,199 | 13 | 9.8% |
| Unspecified | $35,011 | 10 | 5.2% |
| Travel and Lodging | $28,299 | 119 | 4.2% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Trial of the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 in Adult Patients | Astellas Pharma Global Development | $29,920 | 0 |
| Retrospective Analysis of Patient Outcomes and Clinical Characteristics in Recovered COVID-19 Patients with Pharmacological Stress Tests in the United States | Astellas Pharma Global Development | $5,091 | 1 |
Top Doctors Receiving Payments for Lexiscan
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Fortunato Neglia | — | Maxwell, IA | $110,792 | 65 |
| , MD | Nuclear Medicine | Cleveland, OH | $33,445 | 38 |
| , MD | Cardiovascular Disease | Dallas, TX | $28,164 | 26 |
| , M.D | Interventional Cardiology | Camp Hill, PA | $20,074 | 14 |
| , M.D | Cardiovascular Disease | Long Beach, CA | $19,988 | 17 |
| , MD | Cardiovascular Disease | Rochester, NY | $16,096 | 17 |
| , M.D | Cardiovascular Disease | Chicago, IL | $15,268 | 12 |
| , MD | Internal Medicine | Boston, MA | $14,991 | 10 |
| , MD | Internal Medicine | Circleville, OH | $14,730 | 3 |
| , MD | Nuclear Cardiology | Hawthorne, NY | $13,703 | 11 |
| , MD | Cardiovascular Disease | Jeffersonville, IN | $13,293 | 12 |
| , M.D | Nuclear Cardiology | New Haven, CT | $12,806 | 9 |
| , M.D | Cardiovascular Disease | Houston, TX | $11,967 | 6 |
| , M.D | Nuclear Medicine | San Diego, CA | $11,251 | 14 |
| , M.D | Cardiovascular Disease | Los Angeles, CA | $10,861 | 10 |
| , M.D | Internal Medicine | Detroit, MI | $10,426 | 11 |
| , MD | Cardiovascular Disease | Seattle, WA | $10,318 | 17 |
| , MD | Cardiovascular Disease | Colonial Heights, VA | $9,239 | 7 |
| , M.D | Specialist | Chicago, IL | $8,103 | 2 |
| , D.O | Cardiovascular Disease | Birmingham, AL | $7,287 | 14 |
| , M.D | Cardiovascular Disease | Jacksonville, FL | $6,826 | 15 |
| , MD | Cardiovascular Disease | Hermitage, PA | $6,538 | 6 |
| , M.D | Specialist | Beverly Hills, CA | $6,510 | 12 |
| , M.D | Internal Medicine | Detroit, MI | $6,474 | 9 |
| , MD | Cardiovascular Disease | Lakeland, FL | $6,178 | 15 |
Manufacturing Companies
- Astellas Pharma US Inc $599,807
- Astellas Pharma Global Development $77,452
Product Information
- Type Drug
- Total Payments $677,259
- Total Doctors 5,096
- Transactions 9,980
About Lexiscan
Lexiscan is a drug associated with $677,259 in payments to 5,096 healthcare providers, recorded across 9,980 transactions in the CMS Open Payments database. The primary manufacturer is Astellas Pharma US Inc.
Payment data is available from 2017 to 2023. In 2023, $38,897 was paid across 159 transactions to 141 doctors.
The most common payment nature for Lexiscan is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($286,560, 42.3% of total).
Lexiscan is associated with 2 research studies, including "Clinical Trial of the Safety and Efficacy of Regadenoson for Moderate to Severe COVID-19 in Adult Patients" ($29,920).